Our Mission:
To bring advanced in-vitro diagnostic assays from human medicine, academic research, and pharmacology clinical trials testing to veterinary medicine to improve the quality of care for companion animals.

VDxI achieves this by collaborating with leading researchers and academia to validate the performance of these tests in "real-life" terms and provide education and reference lab services to veterinarians nationwide.

Founded in 2006, VDxI is a privately held company located in southern California, home to many high technology companies.

Our mission began by developing an innovative species specific biomarker, called NT-proBNP, which is often used in human diagnostics to detect heart disease. Now available through IDEXX Laboratories as "CardioPet", it offers pet owners and veterinarians a convenient and cost-effective means to detect heart disease at a very early stage.

VDxI continues to pursue biomarkers in a variety of disease states for sepsis, cancer, osteoarthritis, and other challenging situations facing the veterinarian.